Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Segment Revenue, Operating Income and Depreciation and Amortization

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2019			2018			2017
Revenue:
Medical Device	$	78,353		$	60,513		$	53,983
In Vitro Diagnostics		21,724			20,823			19,129
Total revenue	$	100,077		$	81,336		$	73,112
Operating income (loss):
Medical Device	$	4,794		$	(8,478	)	$	6,902
In Vitro Diagnostics		10,620			8,619			8,293
Total segment operating income		15,414			141			15,195
Corporate		(8,945	)		(8,940	)		(8,092	)
Total operating income (loss)	$	6,469		$	(8,799	)	$	7,103
Depreciation and amortization:
Medical Device	$	5,811		$	5,376		$	4,453
In Vitro Diagnostics		464			394			412
Corporate		1,037			661			690
Total depreciation and amortization	$	7,312		$	6,431		$	5,555

Revenue from Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

	2019			2018			2017
Abbott		19	%		11	%	N/A
Medtronic		14	%		16	%		18	%

Geographic Revenue and Long-lived Assets

Geographic revenue was as follows for the years ended September 30:

	2019			2018			2017
Domestic		81	%		79	%		77	%
Foreign		19	%		21	%		23	%

Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30:

	2019		2018
U.S.	$	24,450	$	26,652
Ireland		19,524		21,174